These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20209589)

  • 1. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review.
    Saab S; Waterman B; Chi AC; Tong MJ
    Liver Transpl; 2010 Mar; 16(3):300-7. PubMed ID: 20209589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.
    Holt D; Thomas R; Van Thiel D; Brems JJ
    Arch Surg; 2002 May; 137(5):572-5; discussion 575-6. PubMed ID: 11982471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
    Katz LH; Paul M; Guy DG; Tur-Kaspa R
    Transpl Infect Dis; 2010 Aug; 12(4):292-308. PubMed ID: 20002355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
    Dodson SF; Bonham CA; Geller DA; Cacciarelli TV; Rakela J; Fung JJ
    Transplantation; 1999 Oct; 68(7):1058-61. PubMed ID: 10532552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and treatment strategies for de novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Dong C; Gao W; Ma N; Sun C; Zheng WP; Wang K; Shen ZY
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 27933716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine.
    Jain A; Orloff M; Abt P; Kashyap R; Mohanka R; Lansing K; Kelley M; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3187-9. PubMed ID: 16213345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation.
    Katz LH; Tur-Kaspa R; Guy DG; Paul M
    Cochrane Database Syst Rev; 2010 Jul; (7):CD006005. PubMed ID: 20614442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
    Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers.
    Lee S; Kim JM; Choi GS; Park JB; Kwon CH; Choe YH; Joh JW; Lee SK
    Liver Transpl; 2016 Feb; 22(2):247-51. PubMed ID: 26600319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention and treatment of hepatitis B recurrence after liver transplantation].
    Zhang XL; Zhu XF; Shi HJ; Cui SZ; Tang YQ; Ba MC; Wang JK; Wang B; Lu Q; Zhao HY; Wu YB; Li ML
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(9):606-9. PubMed ID: 18646715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.